Dorsett-Martin WA, Persons B, Wysocki A, Lineaweaver W, et al.
Wounds : a compendium of clinical research and practice. Date of publication 2008 Nov 1;volume 20(11):292-8.
1. Wounds. 2008 Nov;20(11):292-8.
New Topical Agents for Treatment of Partial-thickness Burns in Children: A
Review of Published Outcome Studies.
Dorsett-Martin WA(1), Persons B, Wysocki A, Lineaweaver W.
Author information:
(1)Division of Plastic Surgery, University of Mississippi Medical Center,
Jackson, Mississippi; Email: martin@surgery.umsmed.edu.
Evidence-based choices for treating burns in children are not well defined.
Skin substitutes and contemporary dressings offer potential advantages over
traditional treatment with topical antimicrobial agents in treating
partial-thickness burns. Newer treatment modalities may reduce morbidity,
financial burdens, and scarring by accelerating healing. Reports of pediatric
burn management from 1997 to 2007 were reviewed to compare agent performance with
outcome measures such as healing time, pain moderation, cosmetic results, and
hospital costs. Transcyte™ (Smith & Nephew, London), Biobrane® (Bertek
Pharmaceuticals Inc, Morgantown, WV), beta-glucan collagen, and Mepitel®
(Mölnlycke, Göteborg, Sweden) have been reported as superior to silver
sulfadiazine (SSD) in achieving faster healing times and decreased pain in
pediatric patients. Initial reports describing the outcomes achieved with these
new agents indicate that they may offer clinical advantages in the treatment of
partial-thickness burns in children. Increased costs of the new products appeared
to be offset by decreases in hospital stay, nursing care time and pain
medications. The existing literature is not conclusive, and prospective trials
with standardized outcome measures are needed to better define the role of these
agents. .
PMID: 25941828
